Annals of Hematology

, Volume 83, Issue 7, pp 471–473 | Cite as

Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major

Case Report

Abstract

Cardiac complications caused by iron deposition are major causes of death in patients with β-thalassemia major. Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX). Furthermore, combined therapy with L1 and DFX produced an additive or synergistic iron chelating effect. We report the successful treatment of severe heart failure in two patients with β-thalassemia major with the combined therapy. Magnetic resonance images showed a marked recovery of signal intensity in the heart, indicating a significant reduction of iron load in the heart. No significant adverse effects were noted. Therefore, combined therapy with L1 and DFX should be considered in patients with β-thalassemia major and cardiac complications.

Keywords

β-thalassemia major Heart failure Deferiprone Desferrioxamine Combined therapy 

References

  1. 1.
    Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516–520CrossRefPubMedGoogle Scholar
  2. 2.
    Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361–364CrossRefPubMedGoogle Scholar
  3. 3.
    Giardina PJ, Grady RW (2001) Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 38:360–366CrossRefPubMedGoogle Scholar
  4. 4.
    Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130–138CrossRefPubMedGoogle Scholar
  5. 5.
    Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C (2002) The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 139:50–58CrossRefPubMedGoogle Scholar
  6. 6.
    Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 121:187–189PubMedGoogle Scholar
  7. 7.
    Jessup M, Manno CS (1998) Diagnosis and management of iron-induced heart disease in Cooley’s anemia. Ann N Y Acad Sci 850:242–250PubMedGoogle Scholar
  8. 8.
    Modell B, Khan M, Darlison M (2000) Survival in beta thalassemia major in the United Kingdom: data from the UK Thalassemia Register. Lancet 355:2051–2052CrossRefPubMedGoogle Scholar
  9. 9.
    Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M (1993) Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 103:1276-1278PubMedGoogle Scholar
  10. 10.
    Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171–2179CrossRefPubMedGoogle Scholar
  11. 11.
    Richardson DR (2002) Deferiprone: greater efficacy at depleting myocardial than hepatic iron? Lancet 360:501–502CrossRefPubMedGoogle Scholar
  12. 12.
    Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489–496PubMedGoogle Scholar
  13. 13.
    Hoffbrand V (2001) Iron chelation: 2 better than 1? Blood 97:586Google Scholar
  14. 14.
    Mavrogeni SI, Maris T, Gouliamos A, Vlahos L, Kremastinos DT (1998) Myocardial iron deposition in beta-thalassemia studies by magnetic resonance imaging. Int J Card Imaging 14:117–122CrossRefPubMedGoogle Scholar
  15. 15.
    Olivieri NF, Brittenham BM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339:417–423PubMedGoogle Scholar
  16. 16.
    Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patient. Br J Haematol 101:413–415CrossRefPubMedGoogle Scholar
  17. 17.
    Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR (2002) Lack of progressive hepatic fibrosis during long term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100:1566–1569CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • K. H. Wu
    • 1
  • J. S. Chang
    • 1
  • C. H. Tsai
    • 1
  • C. T. Peng
    • 1
  1. 1.Department of PediatricsChina Medical University HospitalTaichungTaiwan

Personalised recommendations